Author

T. Fleischer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 6

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 6 Assay:DNA methylation· 5 Approach:statistical model· 5 Assay:bulk RNA-seq· 3 Research Focus:chromatin & epigenetic regulation· 3 Research Focus:gene regulatory network inference· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2

Frequent Co-Authors

V. N. Kristensen· 6 shared J. Ankill· 4 shared A. Mathelier· 3 shared X. Tekpli· 3 shared A.-L. Borresen-Dale· 2 shared M. R. Aure· 2 shared O. Engebraaten· 2 shared Oslo Breast Cancer Research Consortium (OSBREAC)· 2 shared

Activity by Year

2018-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersCancer Biology

V. N. Kristensen

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Integrative pan-cancer analysis reveals a common architecture of dysregulated transcriptional networks characterized by loss of enhancer methylation

J. Ankill, Z. Zhao, X. Tekpli, E. H. Kure, V. N. Kristensen, A. Mathelier, T. Fleischer

This study identifies common dysregulated transcriptional networks across cancers linked to loss of enhancer methylation through pan-cancer emQTL analysis.

bioRxiv · Sep 22, 2023Cancer Biology

An integrated 'omics approach highlights the role of epigenetic events to explain and predict response to neoadjuvant chemotherapy and bevacizumab

T. Fleischer, M. H. Haugen, J. Ankill, L. Silwal-Pandit, A.-L. Borresen-Dale, I. Hedenfalk, T. Hatschek, J. Tost, O. Engebraaten, V. N. Kristensen

This study uses an integrated omics approach to show that DNA methylation at enhancer CpGs can predict response to neoadjuvant chemotherapy and bevacizumab in ER-positive patients.

bioRxiv · Jul 6, 2022 · PreprintCancer Biology

Pioneer transcription factors are associated with the modulation of DNA methylation patterns across cancers

R. Berhanu Lemma, T. Fleischer, E. Martinsen, M. Ledsaak, V. N. Kristensen, R. Eskeland, O. S. Gabrielsen, A. Mathelier

The paper identifies 13 transcription factors associated with DNA methylation modulation in cancer, showing their role in chromatin structure and transcription through emQTL analysis and experimental validation.

bioRxiv · May 10, 2021Cancer Biology

Crosstalk between microRNA expression and DNA methylation drive the hormone-dependent phenotype of breast cancer

M. R. Aure, T. Fleischer, S. Bjorklund, J. Ankill, J. A. Castro-Mondragon, Oslo Breast Cancer Research Consortium (OSBREAC), A.-L. Borresen-Dale, K. K. Sahlberg, A. Mathelier, X. Tekpli, V. N. Kristensen

The paper investigates how microRNA expression and DNA methylation interact to drive hormone-dependent breast cancer phenotypes by analyzing two breast cancer cohorts.

Genome Medicine · Apr 29, 2021Peer-reviewedCancer Biology

Epigenetic alterations at distal enhancers are linked to proliferation in human breast cancer

J. Ankill, M. R. Aure, S. Bjorklund, S. Langberg, Oslo Breast Cancer Research Consortium (OSBREAC), V. N. Kristensen, V. Vitelli, X. Tekpli, T. Fleischer

This study identifies epigenetic alterations at distal enhancers linked to proliferation in breast cancer through genome-wide emQTL analysis and chromatin looping.

bioRxiv · Apr 14, 2021Cancer Biology

Towards personalized computer simulation of breast cancer treatment: a multi-scale pharmacokinetic and pharmacodynamic model informed by multi-type patient data

X. Lai, O. Geier, T. Fleischer, O. Garred, E. F. Borgen, S. Funke, S. Kumar, M. E. Rognes, T. Seierstad, A.-L. Boerresen-Dale, V. N. Kristensen, O. Engebraaten, A. Kohn-Luque, A. Frigessi

This study develops a multi-scale pharmacokinetic and pharmacodynamic model of breast cancer treatment, personalized with patient data to simulate and improve treatment outcomes.

bioRxiv · Jul 19, 2018Cancer Biology